FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134929243> ?p ?o ?g. }

• W3134929243 endingPage "206" @default.
• W3134929243 startingPage "201" @default.
• W3134929243 abstract "The selective β3-adrenoceptor agonist mirabegron, an established alternative to antimuscarinic therapy for patients with overactive bladder, induces additional effects against receptors, transporters, and hepatic enzymes. The present study aimed to elucidate the effects of mirabegron on muscarinic receptors in the rat bladder using radioligand binding and functional assays. Mirabegron (0.1-100 μM) inhibited specific [N-methyl-3H]scopolamine methyl chloride binding in the bladder and other tissues of rats in a concentration-dependent manner. Binding affinity in the bladder was similar to that in the heart and significantly higher than those in the submaxillary gland and brain. Mirabegron induced the concentration-dependent relaxation of carbachol-induced contractions in the rat isolated bladder. Further analyses using a two-site model revealed that the relative quantities of high- and low-affinity components for mirabegron were 44.5% and 55.5%, respectively. Respective pEC50 values were 7.06 and 4.97. Based on the receptor binding affinity and pharmacokinetics of mirabegron, muscarinic receptor occupancy in the human bladder for 24 hours after the administration of a single oral dose of 50 mg mirabegron was 37%-76%. The present results demonstrate for the first time that mirabegron may relax the detrusor smooth muscle not only by β3-adrenoceptor activation but also muscarinic receptor blockade. SIGNIFICANCE STATEMENT: Mirabegron, the first selective β3-adrenoceptor agonist, represents an alternative to antimuscarinic agents for management of overactive bladder (OAB). The present study aimed to clarify whether mirabegron directly binds to muscarinic receptors and affects cholinergic agonist-induced contractions in rat urinary bladder and to predict muscarinic receptor occupancy in human bladder after oral administration of mirabegron. The results demonstrated that mirabegron therapy for patients with OAB may be due not only to β3-adrenoceptor activation but also muscarinic receptor blockade." @default.
• W3134929243 created "2021-03-15" @default.
• W3134929243 creator A5019991071 @default.
• W3134929243 creator A5027937630 @default.
• W3134929243 creator A5028573628 @default.
• W3134929243 creator A5051609821 @default.
• W3134929243 creator A5069414236 @default.
• W3134929243 creator A5073294948 @default.
• W3134929243 creator A5084435666 @default.
• W3134929243 date "2021-03-03" @default.
• W3134929243 modified "2023-10-17" @default.
• W3134929243 title "Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder" @default.
• W3134929243 cites W1522474914 @default.
• W3134929243 cites W1787320721 @default.
• W3134929243 cites W1945095845 @default.
• W3134929243 cites W1963810625 @default.
• W3134929243 cites W1976690934 @default.
• W3134929243 cites W1994919446 @default.
• W3134929243 cites W2002731116 @default.
• W3134929243 cites W2012678551 @default.
• W3134929243 cites W2033285271 @default.
• W3134929243 cites W2033901716 @default.
• W3134929243 cites W2054615701 @default.
• W3134929243 cites W2057563553 @default.
• W3134929243 cites W2066727345 @default.
• W3134929243 cites W2086779454 @default.
• W3134929243 cites W2104967317 @default.
• W3134929243 cites W2109033354 @default.
• W3134929243 cites W2169016904 @default.
• W3134929243 cites W2261817895 @default.
• W3134929243 cites W2462584750 @default.
• W3134929243 cites W2464647978 @default.
• W3134929243 cites W2553725658 @default.
• W3134929243 cites W2606250578 @default.
• W3134929243 cites W2609217804 @default.
• W3134929243 cites W2620768995 @default.
• W3134929243 cites W2773037751 @default.
• W3134929243 cites W2800933213 @default.
• W3134929243 cites W2801558063 @default.
• W3134929243 cites W2805086678 @default.
• W3134929243 cites W2805388448 @default.
• W3134929243 cites W2904063024 @default.
• W3134929243 cites W414602664 @default.
• W3134929243 cites W613559724 @default.
• W3134929243 doi "https://doi.org/10.1124/jpet.120.000301" @default.
• W3134929243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33658313" @default.
• W3134929243 hasPublicationYear "2021" @default.
• W3134929243 type Work @default.
• W3134929243 sameAs 3134929243 @default.
• W3134929243 citedByCount "6" @default.
• W3134929243 countsByYear W31349292432021 @default.
• W3134929243 countsByYear W31349292432022 @default.
• W3134929243 countsByYear W31349292432023 @default.
• W3134929243 crossrefType "journal-article" @default.
• W3134929243 hasAuthorship W3134929243A5019991071 @default.
• W3134929243 hasAuthorship W3134929243A5027937630 @default.
• W3134929243 hasAuthorship W3134929243A5028573628 @default.
• W3134929243 hasAuthorship W3134929243A5051609821 @default.
• W3134929243 hasAuthorship W3134929243A5069414236 @default.
• W3134929243 hasAuthorship W3134929243A5073294948 @default.
• W3134929243 hasAuthorship W3134929243A5084435666 @default.
• W3134929243 hasBestOaLocation W31349292431 @default.
• W3134929243 hasConcept C116289061 @default.
• W3134929243 hasConcept C126322002 @default.
• W3134929243 hasConcept C126894567 @default.
• W3134929243 hasConcept C134018914 @default.
• W3134929243 hasConcept C142724271 @default.
• W3134929243 hasConcept C170493617 @default.
• W3134929243 hasConcept C185592680 @default.
• W3134929243 hasConcept C204787440 @default.
• W3134929243 hasConcept C2778164427 @default.
• W3134929243 hasConcept C2778938600 @default.
• W3134929243 hasConcept C2778941218 @default.
• W3134929243 hasConcept C2778988552 @default.
• W3134929243 hasConcept C2779762690 @default.
• W3134929243 hasConcept C33789571 @default.
• W3134929243 hasConcept C71924100 @default.
• W3134929243 hasConcept C98274493 @default.
• W3134929243 hasConceptScore W3134929243C116289061 @default.
• W3134929243 hasConceptScore W3134929243C126322002 @default.
• W3134929243 hasConceptScore W3134929243C126894567 @default.
• W3134929243 hasConceptScore W3134929243C134018914 @default.
• W3134929243 hasConceptScore W3134929243C142724271 @default.
• W3134929243 hasConceptScore W3134929243C170493617 @default.
• W3134929243 hasConceptScore W3134929243C185592680 @default.
• W3134929243 hasConceptScore W3134929243C204787440 @default.
• W3134929243 hasConceptScore W3134929243C2778164427 @default.
• W3134929243 hasConceptScore W3134929243C2778938600 @default.
• W3134929243 hasConceptScore W3134929243C2778941218 @default.
• W3134929243 hasConceptScore W3134929243C2778988552 @default.
• W3134929243 hasConceptScore W3134929243C2779762690 @default.
• W3134929243 hasConceptScore W3134929243C33789571 @default.
• W3134929243 hasConceptScore W3134929243C71924100 @default.
• W3134929243 hasConceptScore W3134929243C98274493 @default.
• W3134929243 hasIssue "2" @default.
• W3134929243 hasLocation W31349292431 @default.
• W3134929243 hasLocation W31349292432 @default.
• W3134929243 hasOpenAccess W3134929243 @default.

• next